After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.

In a tough R&D environment, delivery technology-based new drug development activities by Korean firms are poised to remain robust in 2024.

A bumper December of licensing transactions and acquisitions involving biotech companies brought the feelgood factor back to the sector. But while big spending in the run-up to Christmas may not dent pharma’s credit cards, it might crimp its investors’ dividends.

Emerging Company Profile: While the UK biotech boasts a promising in-house platform technology, it believes a less restrictive approach to R&D could help it develop superior antibody-drug conjugates for cancer.